Prostate Cancer Diagnostics
Advertisement
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
The panel from UCLA highlights their study on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management.
Cohort 3 of the theranostic trial tested a 64Cu/67Cu-SAR-bisPSMA 12-GBq dose in 6 participants with mCRPC.
Gastrin-releasing peptide receptors may be overexpressed in prostate cancer.
Clarity released updated data on COBRA, confirming that 64Cu-SAR-bisPSMA leads to higher detection of lesions in BCR.
A connection between IDC in prostate biopsy specimens and a lymph node metastatic propensity in PSMA PET or CT?
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Initial data from the COBRA trial confirm that 64Cu-SAR-bisPSMA is safe and “highly” effective in detecting BCR PC.
Dr. Moul offered his insights on how prostate cancer MRI and PSMA PET compare in terms of utility and sensitivity.
Dr. Rettig discusses how PSMA imaging can be utilized for patient monitoring.
Dr. Nicholas Nickols discusses new research into PSMA and looks back at how the field has grown.
At the 2024 PSMA Conference, Dr. Wolfgang Fendler gave an update on the capabilities of PSMA PET in advanced prostate cancer.
The first patient has been dosed in the CLARIFY trial, an investigation into 64Cu-SAR-bisPSMA in prostate cancer.
Clarity announced the second phase of the SECuRE trial's third cohort has commenced, as has the phase 3 CLARIFY trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.